The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...

Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...

Efzimfotase alfa offered numerical, but not statistically significant improvements in patient six-minute walk test values in the HICKORY trial in hypophosphatasia. Credit: Lemberg Vector studio / ...

Rafael Holdings subsidiary, Cyclo Therapeutics is planning to submit a NDA to US regulators for Trappsol Cyclo in NPC despite the primary endpoint miss. Credit: Kateryna Kon / Shutterstock.com. Rafael ...

Oral semaglutide maintains weight-loss progress after injectable GLP-1 therapy, strengthening its case as an oral alternative.

Invivyd’s Covid-targeting mAb was proven more safe and tolerable than Pfizer and BioNTech’s Comirnaty as per the trial’s endpoints. Credit: Corona Borealis Studio / Shutterstock.com. Invivyd’s ...

ALS is a fatal neurodegenerative condition with no cure and limited treatment options for symptom management. Credit: Andrzej Rostek/Shutterstock.com. VectorY Therapeutics has expanded the study size ...

Kodiak will file for Zenkuda’s approval in wAMD following these positive results. Credit: recep kart / Shutterstock.com. Kodiak Sciences’ stock has soared by upwards of 90% after securing a duo of ...

The Clinical Trials Arena editorial team brings you the highlights from the IMS 2026 Congress in Glasgow, Scotland. Credit: David A Litman / Shutterstock.com. In recent years, the multiple myeloma ...

The bispecific antibody is intended for treating advanced gastric cancer. Credit: SewCreamStudio/Shutterstock.com. Akeso has commenced a global Phase III clinical ...

With the latest expansion, the trial will consist of two substudies, one focusing on squamous NSCLC and the other on non-squamous NSCLC. Credit: bangoland/Shutterstock.com. Innovent Biologics has ...

Acadia is continuing its Phase III studies on remlifanserin in ADP with some protocol amendments. Credit: Chinnapong / Shutterstock.com. Acadia Pharmaceuticals has deemed the results of its Phase II ...